{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-011124","form_type":"8-K","ticker":"GMED","cik":"0001237831","company_name":"GLOBUS MEDICAL INC","filed_at":"2026-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.673340+00:00","generated_at":"2026-05-16T00:42:08.814228+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Globus Medical Q4 revenue $826.4M (+25.7% YoY); EPS $1.03 GAAP / $1.28 non-GAAP","bullets":["Q4 worldwide net sales $826.4M, up 25.7% YoY; base business ex-Nevro up 10.6%.","GAAP diluted EPS $1.03 (vs $0.19); non-GAAP diluted EPS $1.28 (vs $0.84), up 52.1%.","Full year 2025 revenue $2,938.9M (+16.7%); GAAP EPS $3.92; non-GAAP EPS $3.98.","2026 guidance: revenue $3.18-3.22B; non-GAAP EPS raised to $4.40-4.50 from $4.30-4.40.","US Spine revenue grew 10% in Q4; Enabling Technologies grew 19% over prior-year quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-011124","json":"https://secwatch.observer/filing/0001628280-26-011124.json","markdown":"https://secwatch.observer/filing/0001628280-26-011124.md","text":"https://secwatch.observer/filing/0001628280-26-011124.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1237831/000162828026011124/0001628280-26-011124-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1237831/000162828026011124/gmed-20260224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:42:08.814228+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}